Source: Annual Congress 2002 - Early diagnosis and prevention in children with atopy
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. L. Maksimovic, S. Radic, M. Popovic, D. Begovic, M. Voros (). Effects of oromucosal immunotherapy (SLIT) in children with respiratory allergy. Eur Respir J 2002; 20: Suppl. 38, 3270

Member's Comments

No comment yet.

Related content which might interest you: Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005 Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of 300IR 5-grass pollen sublingual tablet in allergic patients with and without asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Efficacy and safety of the short term immunotherapy (SIT) in allergic rhinoconjunctivitis (AR) Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER) Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002 Budesonide and loratadine in the treatment of allergic rhinitis in children Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013